Literature DB >> 26407872

Supportive or detrimental roles of P2Y receptors in brain pathology?--The two faces of P2Y receptors in stroke and neurodegeneration detected in neural cell and in animal model studies.

Daniel Förster1, Georg Reiser2.   

Abstract

This review describing the role of P2Y receptors in neuropathological conditions focuses on obvious differences between results demonstrating either a role in neuroprotection or in neurodegeneration, depending on in vitro and in vivo models. Such critical juxtaposition puts special emphasis on discussions of beneficial and detrimental effects of P2Y receptor agonists and antagonists in these models. The mechanisms reported to underlie the protection in vitro include increased expression of oxidoreductase genes, like carbonyl reductase and thioredoxin reductase; increased expression of inhibitor of apoptosis protein-2; extracellular signal-regulated kinase- and Akt-mediated antiapoptotic signaling; increased expression of Bcl-2 proteins, neurotrophins, neuropeptides, and growth factors; decreased Bax expression; non-amyloidogenic APP shedding; and increased neurite outgrowth in neuronal cells. Animal studies investigating the influence of P2Y receptors in middle cerebral artery occlusion (MCAO) models for stroke prove beneficial effects of P2Y receptor antagonists. In MCAO mice and rats, the application of broad-range P2 receptor antagonists decreased the infarct volume and improved neurological outcome. Moreover, antagonists of the P2Y1 receptor, one of the most abundant P2Y receptor subtypes in brain tissue, decreased neuronal loss and improved spatial memory in rats after traumatic brain injury (TBI). Currently available data show a discrepancy between in vitro and in vivo models concerning the benefits of P2Y receptor activation in pathological conditions. In vitro models demonstrate protection by P2Y receptor agonists, but in vivo P2Y receptor activation deteriorates the outcome after MCAO and controlled cortical impact brain injury, a TBI model. To broaden the scope of the review, we additionally discuss publications that demonstrate detrimental effects of P2Y receptor agonists in vitro and publications showing protective effects of agonists in vivo. All these studies help to better understand the significant role of P2Y receptors especially in stroke models and to develop pharmacological strategies for the treatment of stroke.

Entities:  

Keywords:  Apoptosis; Astrocytes; Brain; MCAO; Neuroinflammation; Neurons; Neuroprotection; P2Y receptor

Mesh:

Substances:

Year:  2015        PMID: 26407872      PMCID: PMC4648799          DOI: 10.1007/s11302-015-9471-6

Source DB:  PubMed          Journal:  Purinergic Signal        ISSN: 1573-9538            Impact factor:   3.765


  98 in total

Review 1.  Molecular physiology of P2X receptors and ATP signalling at synapses.

Authors:  B S Khakh
Journal:  Nat Rev Neurosci       Date:  2001-03       Impact factor: 34.870

Review 2.  UDP facilitates microglial phagocytosis through P2Y6 receptors.

Authors:  Kazuhide Inoue
Journal:  Cell Adh Migr       Date:  2007-07-27       Impact factor: 3.405

Review 3.  Neuronal regulation of immune responses in the central nervous system.

Authors:  Li Tian; Heikki Rauvala; Carl G Gahmberg
Journal:  Trends Immunol       Date:  2009-01-12       Impact factor: 16.687

4.  Mechanisms of protein kinase D activation in response to P2Y(2) and P2X7 receptors in primary astrocytes.

Authors:  Luz María G Carrasquero; Esmerilda G Delicado; Lucía Sánchez-Ruiloba; Teresa Iglesias; Maria Teresa Miras-Portugal
Journal:  Glia       Date:  2010-06       Impact factor: 7.452

Review 5.  Purinergic signalling: from normal behaviour to pathological brain function.

Authors:  Geoffrey Burnstock; Ute Krügel; Maria P Abbracchio; Peter Illes
Journal:  Prog Neurobiol       Date:  2011-09-01       Impact factor: 11.685

6.  P2Y2 nucleotide receptors enhance alpha-secretase-dependent amyloid precursor protein processing.

Authors:  Jean M Camden; Ann M Schrader; Ryan E Camden; Fernando A González; Laurie Erb; Cheikh I Seye; Gary A Weisman
Journal:  J Biol Chem       Date:  2005-03-18       Impact factor: 5.157

7.  Nucleotides released from Aβ₁₋₄₂ -treated microglial cells increase cell migration and Aβ₁₋₄₂ uptake through P2Y₂ receptor activation.

Authors:  Hye Jung Kim; Deepa Ajit; Troy S Peterson; Yanfang Wang; Jean M Camden; W Gibson Wood; Grace Y Sun; Laurie Erb; Michael Petris; Gary A Weisman
Journal:  J Neurochem       Date:  2012-03-14       Impact factor: 5.372

Review 8.  Inflammation in intracerebral hemorrhage: from mechanisms to clinical translation.

Authors:  Yu Zhou; Yanchun Wang; Jian Wang; R Anne Stetler; Qing-Wu Yang
Journal:  Prog Neurobiol       Date:  2013-11-26       Impact factor: 11.685

9.  P2Y receptors activate neuroprotective mechanisms in astrocytic cells.

Authors:  Nataliya E Chorna; Laura I Santiago-Pérez; Laurie Erb; Cheikh I Seye; Joseph T Neary; Grace Y Sun; Gary A Weisman; Fernando A González
Journal:  J Neurochem       Date:  2004-10       Impact factor: 5.372

Review 10.  Dysregulation of glutathione homeostasis in neurodegenerative diseases.

Authors:  William M Johnson; Amy L Wilson-Delfosse; John J Mieyal
Journal:  Nutrients       Date:  2012-10-09       Impact factor: 5.717

View more
  8 in total

Review 1.  Purinergic Signalling: Therapeutic Developments.

Authors:  Geoffrey Burnstock
Journal:  Front Pharmacol       Date:  2017-09-25       Impact factor: 5.810

Review 2.  Targeting Neuroinflammation via Purinergic P2 Receptors for Disease Modification in Drug-Refractory Epilepsy.

Authors:  Tobias Engel; Jonathon Smith; Mariana Alves
Journal:  J Inflamm Res       Date:  2021-07-18

Review 3.  Update of P2Y receptor pharmacology: IUPHAR Review 27.

Authors:  Kenneth A Jacobson; Esmerilda G Delicado; Christian Gachet; Charles Kennedy; Ivar von Kügelgen; Beibei Li; M Teresa Miras-Portugal; Ivana Novak; Torsten Schöneberg; Raquel Perez-Sen; Doreen Thor; Beili Wu; Zhenlin Yang; Christa E Müller
Journal:  Br J Pharmacol       Date:  2020-04-06       Impact factor: 9.473

Review 4.  The Metabotropic Purinergic P2Y Receptor Family as Novel Drug Target in Epilepsy.

Authors:  Mariana Alves; Edward Beamer; Tobias Engel
Journal:  Front Pharmacol       Date:  2018-03-07       Impact factor: 5.810

Review 5.  Purinergic signaling in infectious diseases of the central nervous system.

Authors:  Vinícius Santos Alves; Raíssa Leite-Aguiar; Joyce Pereira da Silva; Robson Coutinho-Silva; Luiz Eduardo Baggio Savio
Journal:  Brain Behav Immun       Date:  2020-07-24       Impact factor: 7.217

Review 6.  Role of the Platelets and Nitric Oxide Biotransformation in Ischemic Stroke: A Translative Review from Bench to Bedside.

Authors:  Maciej Bladowski; Jakub Gawrys; Damian Gajecki; Ewa Szahidewicz-Krupska; Anna Sawicz-Bladowska; Adrian Doroszko
Journal:  Oxid Med Cell Longev       Date:  2020-08-28       Impact factor: 6.543

Review 7.  Purinergic Receptors in Neurological Diseases With Motor Symptoms: Targets for Therapy.

Authors:  Ágatha Oliveira-Giacomelli; Yahaira Naaldijk; Laura Sardá-Arroyo; Maria C B Gonçalves; Juliana Corrêa-Velloso; Micheli M Pillat; Héllio D N de Souza; Henning Ulrich
Journal:  Front Pharmacol       Date:  2018-04-10       Impact factor: 5.810

Review 8.  Purinergic Receptors of the Central Nervous System: Biology, PET Ligands, and Their Applications.

Authors:  Hamideh Zarrinmayeh; Paul R Territo
Journal:  Mol Imaging       Date:  2020 Jan-Dec       Impact factor: 4.488

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.